Regeneron's stock price plummeted 10% to $573.21 after the company announced that its Phase 3 trial of fianlimab combined with cemiplimab failed to reach statistical significance for progression-free survival improvement in first-line melanoma treatment, despite a numeric improvement of 12.3%. The trial's outcome is a significant setback for the company, which had high hopes for the combination therapy. The $REGN stock has been under pressure since the announcement, with investors worried about the impact on future developments.
What's Happening Right Now
The Phase 3 trial results showed that the combination of fianlimab and cemiplimab did not meet the primary endpoint of progression-free survival improvement, with a p-value of 0.07, just missing the statistical significance threshold of 0.05. The company's stock price has been volatile, with a 52-week high of $734.55 and a 52-week low of $441.49. The current stock price of $573.21 represents a 21.5% decline from the 52-week high.
Why It Matters for US Investors
The failed trial has significant implications for US investors who have been betting on Regeneron's pipeline of innovative therapies. The company's $REGN stock is listed on the NASDAQ exchange and has a market capitalization of $63.4 billion. The trial's outcome may impact the company's future revenue growth and profitability, making it essential for investors to reassess their investment thesis. The biotechnology sector as a whole may also be affected, with the NASDAQ Biotechnology Index down 1.2% since the announcement.
What Analysts Are Saying
Analysts at Goldman Sachs have downgraded the $REGN stock from Buy to Neutral, citing the trial's disappointing results and the potential impact on future developments. Analysts at Morgan Stanley have also reduced their price target for the stock from $700 to $600, reflecting the increased uncertainty surrounding the company's pipeline. However, analysts at JPMorgan remain Bullish on the stock, citing the company's strong track record of innovation and its diverse pipeline of therapies.
Key Takeaways
- The Regeneron Phase 3 trial of fianlimab combined with cemiplimab failed to reach statistical significance for progression-free survival improvement in first-line melanoma treatment.
- The company's stock price has plummeted 10% to $573.21 since the announcement.
- The trial's outcome may impact the company's future revenue growth and profitability, making it essential for investors to reassess their investment thesis.
Frequently Asked Questions
What is the current stock price of Regeneron?
The current stock price of Regeneron is $573.21.
What is the impact of the trial's outcome on the biotechnology sector?
The trial's outcome may impact the biotechnology sector as a whole, with the NASDAQ Biotechnology Index down 1.2% since the announcement.
What are analysts saying about the Regeneron stock?
Analysts at Goldman Sachs have downgraded the $REGN stock from Buy to Neutral, while analysts at Morgan Stanley have reduced their price target for the stock from $700 to $600. However, analysts at JPMorgan remain Bullish on the stock.
